In Vitro Cytotoxicity, Protein Binding, Red Blood Cell Partitioning, and Biotransformation of Oxaliplatin

Cancer Research

Volumn 53, Issue 24, 1993, Pages 5970-5976

  Pendyala, L ^a   Creaven, P J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; IPROPLATIN; OXALIPLATIN; PLATINUM; TETRAPLATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CELL SEPARATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MIXTURE; DRUG POTENCY; DRUG STRUCTURE; DRUG TRANSFORMATION; ERYTHROCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; ERYTHROCYTES; HUMAN; ORGANOPLATINUM COMPOUNDS; PROTEIN BINDING; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0027146423     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Extra, J. M. Espie, M. Calvo, F, Ferme, C. Mignot, L. and Marty, M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25: 299-303, 1990.
2. Mathe, G. Kidani, Y. Segiguchi, M. Eriguchi, M. Fredj, G. Peytavin, G. Misset, J. L. Brienza, S. de Vassals, F. Chenu, E. and Bourut, C. Oxalato-platinum or oxaliplatin, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 43: 237-250, 1989.
3. Levi, F. Brienza, S. Focan, C. Perpoint, B. Garufi, C. Gatti, G. La Torre, Y. Gastiaburu, J. Depres, P. and Misset, J.L. A phase II chronopharmacological trial of oxaliplatin (oxaliplatin) against metastatic colorectal cancer. Proc. Am. Assoc. Cancer Res. 32: 185, 1991.
4. Misset, J. L. Kidani, Y. Gastiaburu, J. Jasmin, C. Levi, F, Boughattas, N. Lemai-gre, G. Causanel, S. Brienza, S. Triana, K. Goldschmidt, E. Musset, M. Mauv-ernay, R. Y. and Mathe, G. Oxalatoplatinum (oxaliplatin): experimental and clinical studies. In: S. B. Howell (ed.), Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, pp. 369-375. New York: Plenum Publishing Corp. 1991.
5. Levi, F. Misset, J.-L. Brienza, S. Adam, R. Metzger, G. Itzakhi, M. Caussanel, J.-R. Kunstlinger, F. Lecouturier, S. Descorps-Declere, A. Jasmin, C. Bismuth, H. and Reinberg, A. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer (Phila.), 69: 893-900, 1992.
6. Tashiro, T. Kawada, Y. Sakurai, Y, and Kidani, Y Antitumor activity of a new platinum complex, oxalato-(trans-I-l,2-diaminocyclohexane)platinum (II): new experimental data. Biomed. Pharmacother. 43: 251-260, 1989.
7. Madajewicz, S. Takita, H. Creaven, P. J. Bareniewski, H. Regal, A. M. and Cushman, M. K. Phase II study of iproplatin (IPP) in small cell carcinoma of the lung (SCCL). Proc. Am. Soc. Clin. Oncol. 3: 224, 1984.
8. Tutsch, K. D. Arzoomanian, R. Z. Alberts, D. Feierabend, C. Robins, H. I. and Spriggs, D. R. Phase I trial and pharmacokinetic study of ormaplatin. Proc. Am. Assoc. Cancer Res. 33: 536, 1992.
9. Behrens, B. C. Hamilton, T. C. Masuda, H. Grotzinger, K. R. Whang-Peng, J. Louie, K. G. Knutsen, T. McKoy, W. M. Young, R. C. and Ozols, R.F. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res. 47:414-418,1987.
10. Rubinstein, L. V. Shoemaker, R. H. Paull, K. D. Simon, R. M. Tosini, S. Skehan, P. Scudiero, D. A. Monks, A. and Boyd, M. R. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. 82:1113-1118,1990.
11. Skehan, P. Storeng, R. Scudiero, D. Monks, A. McMahon, J. Vistica, D. Warren, J. T. Bokesch, H. Kenney, S. and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82: 1107-1112, 1990.
12. Holford, N. H. G. and Scheiner, L. B. Understanding the dose-effect relationship: clinical applications of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6: 429-453, 1981.
13. Marquardt, D. W. An algorithm for least squares estimation of nonlinear parameters. SIAM J. Soc. Ind. Appl. Math. 11: 431-441, 1963.
14. Nash, J. C. Compact numerical methods for computers: linear algebra and function minimisation. New York: John Wiley & Sons, 1979.
15. Perez, R. P. O'Dwyer, P. J. Handel, L. M. Ozols, R. F. and Hamilton, T. C. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. Int. J. Cancer, 48: 265-169, 1991.
16. Hills, C. A. Kelland, L. R. Abel, J. Siracky, J. Wilson, A. P. and Harrap, K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer, 59: 527-534, 1989.
17. Mauldin, S. K. Richard, F A. Plescia, M. Wyrick, S. D. Sancar, A. and Chaney, S. G. High-performance liquid chromatographic separation of platinum complexes containing the cis-l,2-diaminocyclohexane carrier ligand. Anal. Biochem. 157:129-143, 1986.
18. Rocci, M. L. Jr. and Jusko, W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Programs Biomed. 16: 203-216, 1983.
19. Jones, M. Siracky, J. Kelland, L. R. and Harrap, K. R. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts. Br. J. Cancer, 67: 24-29, 1993.
20. Kelland, L. R. Murrer, B. A. Abel, G. Giandomenico, C. M. and Mistry, P. Ammine/ amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell line. Cancer Res. 52: 822-828, 1992.
21. Kelland, L. R. Jones, M. Abel, G. Valenti, M. Gwynne, J. and Harrap, K. R. Human ovarian carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother. Pharmacol. 30: 43-50, 1992.
22. Pendyala, L. Molnar, M. V. Schwartz, P. Andrulis, P. J. and Creaven, P. J. Comparison of in vitro cytotoxicity of 5-sulfosalicylate (trans-l,2-diaminocyclohexane)-platinum (SSP) with other platinum (Pt) complexes in human tumor cell lines. Proc. Am. Assoc. Cancer Res. 31: 337, 1990.
23. Pendyala, L. Greco, W. Cowens, J. W. Madajewicz, S. and Creaven, P. J. Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (CHIP) in patients with advanced cancer. Cancer Chemother. Pharmacol. 11: 23-28, 1983.
24. Pendyala, L. Krishnan, B. S. Walsh, J. R. Arakali, A. V. Cowens, J. W. and Creaven, P. J. Studies on the human metabolism of iproplatin. Cancer Chemother. Pharmacol. 25: 10-14, 1989.
25. Pendyala, L. Cowens, J. W. and Creaven, P. J. Studies on the pharmacokinetics and metabolism of cis-dichloro-frans-dihydroxy-bis-isopropylamine platinum(IV) in the dog. Cancer Treat. Rep. 66: 509-516, 1982.
26. Chaney, S. G. Wyrick, S. and Till, G. K. In vitro biotransformations of tetrachloro-(DL-trans)l,2-diaminocyclohexaneplatinum(TV) (ormaplatin) in rat plasma. Cancer Res. 50: 4539-4545, 1990.
27. Van der Vijgh, W.J.F., Lelieveld, P. Klein, I. van Putten, L. M. and Pinedo, H. M. Pharmacokinetics of five platinum compounds in dogs. Proceedings of the 4th International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy, Burlington, Vermont, June 1983.
28. Chaney, S. G. Wyrick, S. and Till, G. K. In vitro biotransformations of tetrachloro-(DL-trans)-l,2-diaminocyclohexaneplatinum(IV) (ormaplatin) in rat plasma. Cancer Res. 50: 4539-4545, 1990.
29. Mauldin, S. K. Plescia, M. Richard, F A. Wyrick, S. D. Voyksner, R. D. and Chaney, S. G. Displacement of the bidentate malonate ligand from (DL-trans)l,2-diaminocyclohexane)-malonato-platinum(II) by physiologically important compounds in vitro. Biochem. Pharmacol. 37: 3321-3333, 1988.
30. Mauldin, S. K. Gibbons, G. Wyrick, S. D. and Chaney, S. G. Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane ligand in the L1210 cell line. Cancer Res. 48: 5136-5144, 1988.
31. Gibbons, G. R. Wyrick, S. and Chaney, S. G. Rapid reduction of tetrachloro(DL-trans)-l,2-diaminocyclohexaneplatinumrV (tetraplatin) in RPMI 1640 tissue culture medium. Cancer Res. 49: 1402-1407, 1989.
32. Chaney, S. G. Gibbons, G. R. Wyrick, S. D. and Podhasky, P. An unexpected biotransformation pathway for tetrachloro(DL-trans)l,2-diaminocyclonexan-eplatinum(IV) (tetraplatin) in the L1210 cell line. Cancer Res. 51: 969-973, 1991.
33. Perez, R. P. Hamilton, T. C. and Ozols R. F Resistance to alkylating agents and cisplatin: insights from ovarian cancer model systems. Pharmacol. Ther. 48: 19-27, 1990.